Gene therapy for cancer is becoming a reality but works best for blood cancers like leukemia and not so well yet in more common ones like lung cancer.
NYS Entity Status
NYS Filing Date
AUGUST 07, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC PROFESSIONAL SERVICE LIMITED LIABILITY COMPANY
2013 - MOVING TOGETHER OCCUPATIONAL THERAPY, PLLC
AROUND THE WEB
- A Rush to Develop ‘Utterly Transformative’ Gene Therapies Against Cancer
By DENISE GRADY - Sunday Jul 23, 2017
- DotCom Therapy Gets Shot at Silicon Valley VCs After Pitch Contest
By Jeff Buchanan - Tuesday Aug 22, 2017
DotCom Therapy, a Madison, WI-based startup that has developed software allowing the dozens of therapists it employs to provide remote speech therapy services to schoolchildren, captured first place in one of Wisconsin’s more closely watched pitch competitions on Monday. The contest DotCom Therapy won was the fourth annual “Pressure Chamber,” which is put on by […]
- FDA Approves First Gene Therapy
Wednesday Aug 30, 2017
The Food and Drug Administration has approved the first gene therapy in the U.S., a long-heralded move for a promising new method of combating cancer. The FDA approved Novartis AG’s Kymriah for certain children and young adults who suffer from a form of leukemia.
- Hiring a shrink could make your company more successful
By Moneyish - Monday Sep 4, 2017
This isn’t the kind of occupational therapy you’re used to. When Jonathan Pellegrin, the former chairman and CEO of publishing company Johnson Hill Press and author of “The Art of Selling the Family Business,” saw trouble brewing at his company, he knew just where to turn: a therapist specializing in workplace issues. With a history...
- Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
By Ben Fidler - Tuesday Sep 12, 2017
Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]